000			03973nam a22003855i 4500
999			_c75973 _d75973 _x1
001			75973
003			ES-MaUEC
005			20240119142142.0
007			cr nn 008mamaa
008			130428s2013 xxu| s |||| 0|eng d
020			_a9781461470700
024	7		_a10.1007/978-1-4614-7070-0 _2doi
040			_aES-MaUEC
050		4	_aRC271.C5 _bM65 2013 EB
082	0	4	_a614.5999
245	0	0	_aMolecular mechanisms of tumor cell resistance to chemotherapy : _btargeted therapies to reverse resistance _cedited by Benjamin Bonavida
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (XIII, 260 p.) _b30 ilustraciones, 23 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v1
505	0		_aPreface -- Multidrug resistance in cancer: a tale of ABC drug transporters -- Multidrug resistance: a role for membrane physics, pH and drug transporters -- Mechanisms and potential therapies for acquired resistance to inhibitors targeting the Raf or MEK kinases in cancer -- Mechanisms of resistance to targeted B-Raf therapies -- Role of β1integrins in the complication and drug resistance against lung cancer: targeting β1integrins to eradicate lung cancer -- Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance -- Overcoming drug resistance through elevation of ROS in cancer -- Cancer stem cells in resistance to cytotoxic drugs: implications in chemotherapy -- Two birds with a stone: molecular cancer therapy targeting signal transduction and DNA repair pathways -- Collateral sensitivity in drug-resistant tumor cells -- Human cancer resistance to trail-apoptotic pathway-targeted therapies -- The dark side of apoptosis -- Index
520			_aPatients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such mechanisms have revealed gene products that directly regulate resistance and are targets for therapy. Of interest, several FDA-approved drugs were able to overcome drug resistance and have been successfully used clinically. They have been used as monotherapy or synergized with other therapies for the treatment of resistant tumors. This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students.
650		4	_aCáncer _xQuimioterapia _0comprobar BNE19951018561 _9674463
650	0	7	_aCáncer _xTratamiento _9174085 _0LocalV _2embne
700	1		_aBonavida, Benjamin _eeditor literario _984738 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-7070-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781461470700
907			_a.b12815913 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aRC271 .C5 M65 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1154529x _z06-04-17
988			_aEBOOK, EBSPRINGERrevisado
998			_am _a_alco _a_vill _b04-05-17 _cm _dz _eb _feng _gxxu _h0